Nestler John E, Reilly Elizabeth R, Cheang Kai I, Bachmann Lorin M, Downs Robert W
Department of Internal Medicine, Medical College of Virginia, Virginia Commonwealth University, P.O. Box 980663, Richmond, VA 23298-0663, USA.
Trans Am Clin Climatol Assoc. 2012;123:209-19; discussion 219-20.
We conducted a pilot project to test the hypothesis that decreasing insulin concentrations with diazoxide would affect parameters of vitamin D in obese women with and without polycystic ovary syndrome (PCOS).
Eight obese women with PCOS and nine matched controls participated in the study. Diazoxide was administered orally 100 mg three times daily for 10 days, and parameters of vitamin D were measured at baseline and end-of-study.
At baseline, women with polycystic ovary syndrome had significantly lower serum 25-hydroxyvitamin D (25[OH]D) levels than controls. After treatment with diazoxide, there were no significant changes in vitamin D parameters when PCOS and control women were evaluated separately. Diazoxide exhibited differential effects on 25(OH)D concentrations in PCOS as compared with normal women (P for interaction=0.045), and serum 25(OH)D levels converged after diazoxide treatment.
Obese women with PCOS had significantly lower serum 25(OH)D levels at baseline than age- and body mass index-matched controls. Short-term administration with diazoxide seemed to have differential effects on 25(OH)D levels in PCOS as compared with control women. Further studies are necessary to confirm this finding.
我们开展了一项试点项目,以检验以下假设:使用二氮嗪降低胰岛素浓度会影响患有和未患有多囊卵巢综合征(PCOS)的肥胖女性的维生素D参数。
八名患有PCOS的肥胖女性和九名匹配的对照者参与了该研究。二氮嗪口服给药,每日三次,每次100毫克,共10天,并在基线和研究结束时测量维生素D参数。
在基线时,患有多囊卵巢综合征的女性血清25-羟基维生素D(25[OH]D)水平显著低于对照组。在分别评估PCOS女性和对照女性时,用二氮嗪治疗后,维生素D参数没有显著变化。与正常女性相比,二氮嗪对PCOS患者的25(OH)D浓度有不同影响(交互作用P值=0.045),且二氮嗪治疗后血清25(OH)D水平趋于一致。
患有PCOS的肥胖女性在基线时血清25(OH)D水平显著低于年龄和体重指数匹配的对照组。与对照女性相比,短期使用二氮嗪似乎对PCOS患者的25(OH)D水平有不同影响。需要进一步研究来证实这一发现。